EXOZ

Over the past six months, eXoZymes' stock has experienced volatility and a downward trend. Key events include graduating from the Shell GameChanger™ Accelerator Program, filing an investor presentation for a proposed public offering, and the CCO outlining the NCTx strategy on a podcast. The Chief Scientific Officer sold 1,500 shares, while the Vice President of Development received a grant of 3,999 common shares. The company reported an increased net loss for FY 2025 and provided updates on its NCTx business. A successful pilot scale run with Cayman Chemical validated eXoZymes' technology. The company launched a redesigned website and updated visual identity. eXoZymes announced the successful achievement of a 100-fold scale-up of its NCT production process. Analysts maintain a cautious stance due to the company's pre-revenue status, widening losses, and ongoing cash burn.